<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Kronox Lab Sciences Ltd. (KRONOX) — Tipsheet</title>
    <link>https://tipsheet.markets/company/kronox/</link>
    <atom:link href="https://tipsheet.markets/company/kronox/feed.xml" rel="self" type="application/rss+xml" />
    <description>Every Tipsheet Editorial note covering Kronox Lab Sciences Ltd. (KRONOX), newest first. Grounded in BSE/NSE primary-source filings.</description>
    <language>en-in</language>
    <lastBuildDate>Mon, 06 Jul 2026 10:22:47 GMT</lastBuildDate>
    <item>
      <title>Kronox Lab&#39;s annual results are a study in flatness</title>
      <link>https://tipsheet.markets/kronox-kronox-lab-s-annual-results-are-a-study-in-flatness-94612/</link>
      <guid isPermaLink="true">https://tipsheet.markets/kronox-kronox-lab-s-annual-results-are-a-study-in-flatness-94612/</guid>
      <pubDate>Thu, 21 May 2026 18:45:44 GMT</pubDate>
      <description>FY26 revenue was ₹101.22 crore, barely above last year&#39;s ₹100.19 crore. Net profit rose to ₹27.66 crore. The dividend is unchanged.</description>
      <content:encoded><![CDATA[<p><em>FY26 revenue was ₹101.22 crore, barely above last year's ₹100.19 crore. Net profit rose to ₹27.66 crore. The dividend is unchanged.</em></p>
<h3>What’s new</h3><ul><li>FY26 revenue grew 1% to ₹101.22 crore from ₹100.19 crore.</li><li>Net profit increased to ₹27.66 crore from ₹25.47 crore.</li><li>Board recommended a final dividend of ₹0.50 per share.</li></ul>
<h3>Why it matters</h3><p>Revenue essentially stood still for a full fiscal year. For a nano-cap with a ₹488 crore market cap, that's stagnation. The profit growth is a positive, but the top line shows no momentum.</p>
<h3>What we’re watching</h3><ul><li>Any strategic commentary from management on breaking out of the ₹100 crore revenue range.</li><li>Whether the profit growth is sustained through margin improvement or is a one-off.</li><li>If the flat top line prompts a strategic pivot in FY27.</li></ul>
<h3>The full read</h3><p>Kronox Lab's FY26 numbers are a picture of stasis. Revenue was <strong>₹101.22 crore</strong>. The year before, it was <strong>₹100.19 crore</strong>. That's a <strong>1%</strong> increase over a full fiscal year. Net profit improved to <strong>₹27.66 crore</strong> from <strong>₹25.47 crore</strong>. A solid gain on the bottom line, but it doesn't mask the flat top line. The dividend stays at <strong>₹0.50</strong> a share. For a <strong>₹488 crore</strong> market cap, the scale is small. The auditor's report is clean. Nothing here moves the stock. It's a routine announcement that confirms the business is running in place.</p>
<p>Primary source: <a href="https://www.bseindia.com/corporates/ann.html?scrip=544187&dur=A">BSE</a> · <a href="https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=KRONOX">NSE</a></p>]]></content:encoded>
      <category>Earnings</category>
      <dc:creator>Tipsheet Editorial</dc:creator>
    </item>
  </channel>
</rss>